Very public run-ins between ex-Sanofi CEO Chris Viehbacher and France's powerful unions were one factor that reportedly cost him his job. Now his replacement, Olivier Brandicourt, will see if he can do any better as he tries to negotiate a deal to significantly boost efficiencies at the company's French production sites.
At Express Scripts, both Sanofi and Regeneron's Praluent and Amgen's Repatha scored a spot on the preferred formulary, which gives both PCSK9 products a chance to snare the pharmacy benefits manager's patients. Read more >>
Count Roche CEO Severin Schwan among those who see digital partnerships as the way Big Pharma can finally take advantage of Big Data. And to his mind, tech companies really need to take advantage of pharma's expertise if they want to get ahead in healthcare. Read more >>
Bayer has a new U.S. pharmaceuticals leader in Habib Dable, who has been with the company since joining in 1994 as a sales representative. Read more >>
POPULAR COMMENT THREADS
Merck's Keytruda is two-for-two with the U.K.'s cost watchdog, nabbing another thumbs-up to treat skin cancer days after the National Institute of Health and Care Excellence signed off on the med for patients who have already received treatment.
In what has turned into a legal trifecta for Pfizer, it has won the dismissal of a lawsuit that claimed the use of the antidepressant Zoloft during pregnancy caused birth defects in a child. The decision comes after Pfizer has won two jury verdicts in recent months over the same claims.
Back in August, the FDA approved Purdue's powerful painkiller, OxyContin, for children ages 11 to 16. But nearly two months later, the public backlash hasn't died down.
Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects
Healthcare informatics company Advera Health Analytics delved into FDA postmarketing safety reports and compiled data on Alzheimer's drugs. The firm found that Novartis' Exelon patch, Allergan's Namenda and Eisai's Aricept showed more reports of serious side effects than other drugs, with safety issues ranging from convulsions and gastrointestinal hemorrhage to respiratory failure and sudden death.
When the FDA last year yanked away its initial approval of Ranbaxy's generics of two blockbusters including the heartburn med Nexium, the Indian drugmaker fired back with a lawsuit against the FDA. But Ranbaxy is now owned by Sun Pharmaceutical, which sees no upside to fighting with the agency, and so it has dropped the litigation.
Credit Suisse analyst Vamil Divan is optimistic about sales of Eli Lilly and Boehringer Ingelheim's Jardiance. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77.
From Our Sister Sites
Medtronic announced the first implants of its deep brain stimulation system in conjunction with its bioabsorbable antibacterial envelope to prevent surgical site infections. The milestone occurred at the Barrow Neurological Institute in Phoenix. Medtronic also said it plans to soon make the technology available for use with its neurostimulators for chronic pain and bladder/bowel control disorders.
Onkos Surgical has secured a Series A financing and partnered with MicroPort Orthopedics. The financial details were undisclosed in the company's announcement, but an SEC filing reveals that Onkos recently secured the first $6.1 million of a financing that's expected to total $15.3 million.